Augmenting Reference Pricing of Pharmaceuticals in New Zealand with Strategic Cross-Product Agreements

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.19, Iss.4, 2001-04, pp. : 365-377

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Documentation of Pediatric Drug Safety in Manufacturers' Product Monographs: A Cross-Sectional Evaluation of the Canadian Compendium of Pharmaceuticals and Specialities

By Uppal Navjeet K. Dupuis Lee L. Parshuram Christopher S.

Pediatric Drugs, Vol. 10, Iss. 3, 2008-01 ,pp. : 193-197

Adis International

Access to resources Recommend Favorite

A reference pricing system for Ireland

By Usher Cara Barry Michael

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 12, Iss. 6, 2012-12 ,pp. : 675-677

Informa Healthcare

Access to resources Recommend Favorite

Reference-based pricing discussed

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 375, 2002-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Assessing the Absorption of New Pharmaceuticals

Current Topics in Medicinal Chemistry, Vol. 1, Iss. 5, 2001-11 ,pp. : 385-401

Bentham Science Publishers

Access to resources Recommend Favorite

Farmaindustria, Spain's drug industry federation, has asked the Ministry of Health to introduce its new reference pricing system gradually

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 468, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite